Cargando…

Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities

OBJECTIVE: To investigate the development in the number of applications for authorisation of clinical trials of medicines (CTAs) submitted annually to national competent authorities in 10 Western European member states of the European Union from 2007 to 2015. DESIGN: Registry study. SETTING: Data fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dombernowsky, Tilde, Hædersdal, Merete, Lassen, Ulrik, Thomsen, Simon Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734571/
https://www.ncbi.nlm.nih.gov/pubmed/28698332
http://dx.doi.org/10.1136/bmjopen-2016-015579
_version_ 1783287075787767808
author Dombernowsky, Tilde
Hædersdal, Merete
Lassen, Ulrik
Thomsen, Simon Francis
author_facet Dombernowsky, Tilde
Hædersdal, Merete
Lassen, Ulrik
Thomsen, Simon Francis
author_sort Dombernowsky, Tilde
collection PubMed
description OBJECTIVE: To investigate the development in the number of applications for authorisation of clinical trials of medicines (CTAs) submitted annually to national competent authorities in 10 Western European member states of the European Union from 2007 to 2015. DESIGN: Registry study. SETTING: Data from national competent authorities. PARTICIPANTS: Germany, Italy, Spain, France, the UK, Belgium, the Netherlands, Austria, Denmark and Sweden. Inclusion criteria were Western European member states of the European Union, receiving more than 200 CTAs per year. OUTCOME MEASURES: Summarised number of CTAs and distribution of CTAs by type of sponsor (commercial or non-commercial) and trial phase (I–IV). Average annual growth rates (AAGRs) based on linear regressions. Data were evaluated 2007–2011 and 2012–2015 to compare findings with the European Commission’s statement of a 25% decrease in CTAs in the EU from 2007 to 2011. RESULTS: From 2007 to 2011, the summarised number of CTAs decreased significantly (AAGR −3.9% (p=0.02)), primarily due to a decrease in commercially sponsored CTAs. From 2012 to 2015, the change was insignificant (AAGR 2.6% (p=0.27)), however with a 10% increase from 2014 to 2015 after stagnation from 2012 to 2014. Overall, the number of CTAs and distribution by type of sponsor varied considerably between countries. No distinct trends were observed when evaluating CTAs by type of trial phase. CONCLUSIONS: This study found a significant decrease in the number of CTAs in Western Europe from 2007 to 2011 (AAGR −3.9%). This development is possibly attributable to several factors such as the European Clinical Trials Directive, national and local political decisions, and a potential global shift in clinical trial activity. From 2014 to 2015, the number of CTAs increased markedly (10%). However, it is yet too soon to determine if this constitutes a transient fluctuation or a new trend.
format Online
Article
Text
id pubmed-5734571
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-57345712017-12-20 Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities Dombernowsky, Tilde Hædersdal, Merete Lassen, Ulrik Thomsen, Simon Francis BMJ Open Pharmacology and Therapeutics OBJECTIVE: To investigate the development in the number of applications for authorisation of clinical trials of medicines (CTAs) submitted annually to national competent authorities in 10 Western European member states of the European Union from 2007 to 2015. DESIGN: Registry study. SETTING: Data from national competent authorities. PARTICIPANTS: Germany, Italy, Spain, France, the UK, Belgium, the Netherlands, Austria, Denmark and Sweden. Inclusion criteria were Western European member states of the European Union, receiving more than 200 CTAs per year. OUTCOME MEASURES: Summarised number of CTAs and distribution of CTAs by type of sponsor (commercial or non-commercial) and trial phase (I–IV). Average annual growth rates (AAGRs) based on linear regressions. Data were evaluated 2007–2011 and 2012–2015 to compare findings with the European Commission’s statement of a 25% decrease in CTAs in the EU from 2007 to 2011. RESULTS: From 2007 to 2011, the summarised number of CTAs decreased significantly (AAGR −3.9% (p=0.02)), primarily due to a decrease in commercially sponsored CTAs. From 2012 to 2015, the change was insignificant (AAGR 2.6% (p=0.27)), however with a 10% increase from 2014 to 2015 after stagnation from 2012 to 2014. Overall, the number of CTAs and distribution by type of sponsor varied considerably between countries. No distinct trends were observed when evaluating CTAs by type of trial phase. CONCLUSIONS: This study found a significant decrease in the number of CTAs in Western Europe from 2007 to 2011 (AAGR −3.9%). This development is possibly attributable to several factors such as the European Clinical Trials Directive, national and local political decisions, and a potential global shift in clinical trial activity. From 2014 to 2015, the number of CTAs increased markedly (10%). However, it is yet too soon to determine if this constitutes a transient fluctuation or a new trend. BMJ Publishing Group 2017-07-10 /pmc/articles/PMC5734571/ /pubmed/28698332 http://dx.doi.org/10.1136/bmjopen-2016-015579 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Pharmacology and Therapeutics
Dombernowsky, Tilde
Hædersdal, Merete
Lassen, Ulrik
Thomsen, Simon Francis
Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities
title Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities
title_full Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities
title_fullStr Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities
title_full_unstemmed Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities
title_short Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities
title_sort development in the number of clinical trial applications in western europe from 2007 to 2015: retrospective study of data from national competent authorities
topic Pharmacology and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734571/
https://www.ncbi.nlm.nih.gov/pubmed/28698332
http://dx.doi.org/10.1136/bmjopen-2016-015579
work_keys_str_mv AT dombernowskytilde developmentinthenumberofclinicaltrialapplicationsinwesterneuropefrom2007to2015retrospectivestudyofdatafromnationalcompetentauthorities
AT hædersdalmerete developmentinthenumberofclinicaltrialapplicationsinwesterneuropefrom2007to2015retrospectivestudyofdatafromnationalcompetentauthorities
AT lassenulrik developmentinthenumberofclinicaltrialapplicationsinwesterneuropefrom2007to2015retrospectivestudyofdatafromnationalcompetentauthorities
AT thomsensimonfrancis developmentinthenumberofclinicaltrialapplicationsinwesterneuropefrom2007to2015retrospectivestudyofdatafromnationalcompetentauthorities